Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea (Republic of).
Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 05505, Seoul, Korea (Republic of).
Clin Neuroradiol. 2021 Mar;31(1):125-133. doi: 10.1007/s00062-019-00873-2. Epub 2020 Jan 22.
Thrombosis is one of the main complications of endovascular treatment for unruptured intracranial aneurysms (UIA). This article reports the timing and initial location of thrombosis and prognosis after the use of tirofiban for performing coil embolization for UIA.
This study retrospectively collected 1686 cases of intracranial aneurysms treated with coil embolization from January 2013 to February 2018. Ruptured cases were excluded. The presumed causes and timing of thrombosis, the response after tirofiban administration and the modified Rankin scale (mRS) score at 3 months were reviewed.
Of the 26 patients 76% were female and middle cerebral artery and basilar artery aneurysms accounted for 7 cases. The initial location of thrombosis was related to the stent (n = 14, 53.8%) or coil (n = 12, 46.2%). Of the patients 19 (73.1%) developed thrombosis during the procedure, and 5 patients (19.2%) developed it within 1 day of the procedure. Median duration between the thrombotic procedure and initial thrombosis was 38.5 min, 12 patients were symptomatic but more than half completely recovered after using tirofiban. Good clinical outcome (mRS 0-2) was seen in 92.3%. In the subgroup analysis, median time from the first thrombotic procedure to initial thrombosis within 1 day was 38.0 min (stent-related group) and 35.0 min (coil-related group, p = 0.651).
In most cases of embolization for UIA, thrombosis requiring the use of tirofiban occurs intraprocedurally or on the first day after the procedure. Careful observation of thrombosis during the procedure is important and tirofiban should be used for a better outcome even if the infarction progresses.
血栓形成是未破裂颅内动脉瘤(UIA)血管内治疗的主要并发症之一。本文报道了使用替罗非班进行 UIA 线圈栓塞治疗后血栓形成的时间和初始位置,以及预后。
本研究回顾性收集了 2013 年 1 月至 2018 年 2 月期间 1686 例颅内动脉瘤采用线圈栓塞治疗的病例。排除破裂病例。回顾血栓形成的推测原因和时间、替罗非班使用后的反应以及 3 个月时改良 Rankin 量表(mRS)评分。
26 例患者中,76%为女性,大脑中动脉和基底动脉动脉瘤各 7 例。血栓形成的初始位置与支架(n=14,53.8%)或线圈(n=12,46.2%)有关。19 例(73.1%)患者在手术过程中发生血栓形成,5 例(19.2%)患者在手术后 1 天内发生血栓形成。从血栓形成到首次血栓形成的中位时间为 38.5 分钟,12 例患者出现症状,但使用替罗非班后,超过一半的患者完全恢复。92.3%的患者临床预后良好(mRS 0-2)。在亚组分析中,首次血栓形成后 1 天内发生初始血栓形成的中位时间为 38.0 分钟(支架相关组)和 35.0 分钟(线圈相关组,p=0.651)。
在大多数 UIA 栓塞治疗中,需要使用替罗非班的血栓形成发生在手术过程中或手术后第一天。术中密切观察血栓形成非常重要,即使梗死进展,也应使用替罗非班以获得更好的结果。